IRAK4 and diffuse large B-cell lymphoma: While IRAK4 degraders showed potential in pathway modulation, they did not significantly affect cell apoptosis or growth.330 The ongoing Phase Ia study of KT-413 is further assessing their efficacy in DLBCL patients with MYD88 mutations.